English
简体中文
Total: £ 56.28
Published Date: 2025-04-23 | Pages: 88 | Tables: 89 | Medical Care
The global market for Indolent Systemic Mastocytosis Treatment was valued at US$ 486 million in the year 2024 and is projected to reach a revised size of US$ 706 million by 2031, growing at a CAGR of 5.7% during the forecast period.
Indolent Systemic Mastocytosis (ISM) treatment focuses on managing symptoms and improving quality of life, as the disease typically progresses slowly and has a favorable prognosis. Treatment does not aim to cure but to control symptoms caused by mast cell mediator release, such as flushing, anaphylaxis, gastrointestinal discomfort, and skin lesions. Common therapies include antihistamines (H1 and H2 blockers), leukotriene antagonists, mast cell stabilizers (e.g., cromolyn sodium), and epinephrine for emergency reactions. In some cases, tyrosine kinase inhibitors may be considered if symptoms are refractory.
North American market for Indolent Systemic Mastocytosis Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Indolent Systemic Mastocytosis Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Indolent Systemic Mastocytosis Treatment in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Indolent Systemic Mastocytosis Treatment include Blueprint Medicines Corporation, Allakos Inc., AstraZeneca, Pfizer Inc., Viatrics, Teva Pharmaceuticals, Novartis AG, Merck KGaA, GSK Plc., Deciphera Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Indolent Systemic Mastocytosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Indolent Systemic Mastocytosis Treatment.
The Indolent Systemic Mastocytosis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Indolent Systemic Mastocytosis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Indolent Systemic Mastocytosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Blueprint Medicines Corporation
Allakos Inc.
AstraZeneca
Pfizer Inc.
Viatrics
Teva Pharmaceuticals
Novartis AG
Merck KGaA
GSK Plc.
Deciphera Pharmaceuticals
Sanofi Aventis
Eli Lilly & Company
Segment by Type
Multikinase Inhibitor
Antihistamines
Other
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Indolent Systemic Mastocytosis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Multikinase Inhibitor
1.2.3 Antihistamines
1.2.4 Other
1.3 Market by Application
1.3.1 Global Indolent Systemic Mastocytosis Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Indolent Systemic Mastocytosis Treatment Market Perspective (2020-2031)
2.2 Global Indolent Systemic Mastocytosis Treatment Growth Trends by Region
2.2.1 Global Indolent Systemic Mastocytosis Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Indolent Systemic Mastocytosis Treatment Historic Market Size by Region (2020-2025)
2.2.3 Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Region (2026-2031)
2.3 Indolent Systemic Mastocytosis Treatment Market Dynamics
2.3.1 Indolent Systemic Mastocytosis Treatment Industry Trends
2.3.2 Indolent Systemic Mastocytosis Treatment Market Drivers
2.3.3 Indolent Systemic Mastocytosis Treatment Market Challenges
2.3.4 Indolent Systemic Mastocytosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Indolent Systemic Mastocytosis Treatment Players by Revenue
3.1.1 Global Top Indolent Systemic Mastocytosis Treatment Players by Revenue (2020-2025)
3.1.2 Global Indolent Systemic Mastocytosis Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Top Indolent Systemic Mastocytosis Treatment Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Indolent Systemic Mastocytosis Treatment Revenue
3.4 Global Indolent Systemic Mastocytosis Treatment Market Concentration Ratio
3.4.1 Global Indolent Systemic Mastocytosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Indolent Systemic Mastocytosis Treatment Revenue in 2024
3.5 Global Key Players of Indolent Systemic Mastocytosis Treatment Head office and Area Served
3.6 Global Key Players of Indolent Systemic Mastocytosis Treatment, Product and Application
3.7 Global Key Players of Indolent Systemic Mastocytosis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Indolent Systemic Mastocytosis Treatment Breakdown Data by Type
4.1 Global Indolent Systemic Mastocytosis Treatment Historic Market Size by Type (2020-2025)
4.2 Global Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Type (2026-2031)
5 Indolent Systemic Mastocytosis Treatment Breakdown Data by Application
5.1 Global Indolent Systemic Mastocytosis Treatment Historic Market Size by Application (2020-2025)
5.2 Global Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Indolent Systemic Mastocytosis Treatment Market Size (2020-2031)
6.2 North America Indolent Systemic Mastocytosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025)
6.4 North America Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Indolent Systemic Mastocytosis Treatment Market Size (2020-2031)
7.2 Europe Indolent Systemic Mastocytosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025)
7.4 Europe Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size (2020-2031)
8.2 Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Indolent Systemic Mastocytosis Treatment Market Size (2020-2031)
9.2 Latin America Indolent Systemic Mastocytosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025)
9.4 Latin America Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size (2020-2031)
10.2 Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Blueprint Medicines Corporation
11.1.1 Blueprint Medicines Corporation Company Details
11.1.2 Blueprint Medicines Corporation Business Overview
11.1.3 Blueprint Medicines Corporation Indolent Systemic Mastocytosis Treatment Introduction
11.1.4 Blueprint Medicines Corporation Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.1.5 Blueprint Medicines Corporation Recent Development
11.2 Allakos Inc.
11.2.1 Allakos Inc. Company Details
11.2.2 Allakos Inc. Business Overview
11.2.3 Allakos Inc. Indolent Systemic Mastocytosis Treatment Introduction
11.2.4 Allakos Inc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.2.5 Allakos Inc. Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Indolent Systemic Mastocytosis Treatment Introduction
11.3.4 AstraZeneca Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.3.5 AstraZeneca Recent Development
11.4 Pfizer Inc.
11.4.1 Pfizer Inc. Company Details
11.4.2 Pfizer Inc. Business Overview
11.4.3 Pfizer Inc. Indolent Systemic Mastocytosis Treatment Introduction
11.4.4 Pfizer Inc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.4.5 Pfizer Inc. Recent Development
11.5 Viatrics
11.5.1 Viatrics Company Details
11.5.2 Viatrics Business Overview
11.5.3 Viatrics Indolent Systemic Mastocytosis Treatment Introduction
11.5.4 Viatrics Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.5.5 Viatrics Recent Development
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Details
11.6.2 Teva Pharmaceuticals Business Overview
11.6.3 Teva Pharmaceuticals Indolent Systemic Mastocytosis Treatment Introduction
11.6.4 Teva Pharmaceuticals Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.6.5 Teva Pharmaceuticals Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Indolent Systemic Mastocytosis Treatment Introduction
11.7.4 Novartis AG Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.7.5 Novartis AG Recent Development
11.8 Merck KGaA
11.8.1 Merck KGaA Company Details
11.8.2 Merck KGaA Business Overview
11.8.3 Merck KGaA Indolent Systemic Mastocytosis Treatment Introduction
11.8.4 Merck KGaA Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.8.5 Merck KGaA Recent Development
11.9 GSK Plc.
11.9.1 GSK Plc. Company Details
11.9.2 GSK Plc. Business Overview
11.9.3 GSK Plc. Indolent Systemic Mastocytosis Treatment Introduction
11.9.4 GSK Plc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.9.5 GSK Plc. Recent Development
11.10 Deciphera Pharmaceuticals
11.10.1 Deciphera Pharmaceuticals Company Details
11.10.2 Deciphera Pharmaceuticals Business Overview
11.10.3 Deciphera Pharmaceuticals Indolent Systemic Mastocytosis Treatment Introduction
11.10.4 Deciphera Pharmaceuticals Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.10.5 Deciphera Pharmaceuticals Recent Development
11.11 Sanofi Aventis
11.11.1 Sanofi Aventis Company Details
11.11.2 Sanofi Aventis Business Overview
11.11.3 Sanofi Aventis Indolent Systemic Mastocytosis Treatment Introduction
11.11.4 Sanofi Aventis Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.11.5 Sanofi Aventis Recent Development
11.12 Eli Lilly & Company
11.12.1 Eli Lilly & Company Company Details
11.12.2 Eli Lilly & Company Business Overview
11.12.3 Eli Lilly & Company Indolent Systemic Mastocytosis Treatment Introduction
11.12.4 Eli Lilly & Company Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
11.12.5 Eli Lilly & Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Multikinase Inhibitor
Table 3. Key Players of Antihistamines
Table 4. Key Players of Other
Table 5. Global Indolent Systemic Mastocytosis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Indolent Systemic Mastocytosis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Indolent Systemic Mastocytosis Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Indolent Systemic Mastocytosis Treatment Market Share by Region (2020-2025)
Table 9. Global Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Indolent Systemic Mastocytosis Treatment Market Share by Region (2026-2031)
Table 11. Indolent Systemic Mastocytosis Treatment Market Trends
Table 12. Indolent Systemic Mastocytosis Treatment Market Drivers
Table 13. Indolent Systemic Mastocytosis Treatment Market Challenges
Table 14. Indolent Systemic Mastocytosis Treatment Market Restraints
Table 15. Global Indolent Systemic Mastocytosis Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Indolent Systemic Mastocytosis Treatment Market Share by Players (2020-2025)
Table 17. Global Top Indolent Systemic Mastocytosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Indolent Systemic Mastocytosis Treatment as of 2024)
Table 18. Ranking of Global Top Indolent Systemic Mastocytosis Treatment Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Indolent Systemic Mastocytosis Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Indolent Systemic Mastocytosis Treatment, Headquarters and Area Served
Table 21. Global Key Players of Indolent Systemic Mastocytosis Treatment, Product and Application
Table 22. Global Key Players of Indolent Systemic Mastocytosis Treatment, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Indolent Systemic Mastocytosis Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Indolent Systemic Mastocytosis Treatment Revenue Market Share by Type (2020-2025)
Table 26. Global Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Indolent Systemic Mastocytosis Treatment Revenue Market Share by Type (2026-2031)
Table 28. Global Indolent Systemic Mastocytosis Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Indolent Systemic Mastocytosis Treatment Revenue Market Share by Application (2020-2025)
Table 30. Global Indolent Systemic Mastocytosis Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Indolent Systemic Mastocytosis Treatment Revenue Market Share by Application (2026-2031)
Table 32. North America Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 47. Blueprint Medicines Corporation Company Details
Table 48. Blueprint Medicines Corporation Business Overview
Table 49. Blueprint Medicines Corporation Indolent Systemic Mastocytosis Treatment Product
Table 50. Blueprint Medicines Corporation Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 51. Blueprint Medicines Corporation Recent Development
Table 52. Allakos Inc. Company Details
Table 53. Allakos Inc. Business Overview
Table 54. Allakos Inc. Indolent Systemic Mastocytosis Treatment Product
Table 55. Allakos Inc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 56. Allakos Inc. Recent Development
Table 57. AstraZeneca Company Details
Table 58. AstraZeneca Business Overview
Table 59. AstraZeneca Indolent Systemic Mastocytosis Treatment Product
Table 60. AstraZeneca Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 61. AstraZeneca Recent Development
Table 62. Pfizer Inc. Company Details
Table 63. Pfizer Inc. Business Overview
Table 64. Pfizer Inc. Indolent Systemic Mastocytosis Treatment Product
Table 65. Pfizer Inc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 66. Pfizer Inc. Recent Development
Table 67. Viatrics Company Details
Table 68. Viatrics Business Overview
Table 69. Viatrics Indolent Systemic Mastocytosis Treatment Product
Table 70. Viatrics Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 71. Viatrics Recent Development
Table 72. Teva Pharmaceuticals Company Details
Table 73. Teva Pharmaceuticals Business Overview
Table 74. Teva Pharmaceuticals Indolent Systemic Mastocytosis Treatment Product
Table 75. Teva Pharmaceuticals Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 76. Teva Pharmaceuticals Recent Development
Table 77. Novartis AG Company Details
Table 78. Novartis AG Business Overview
Table 79. Novartis AG Indolent Systemic Mastocytosis Treatment Product
Table 80. Novartis AG Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 81. Novartis AG Recent Development
Table 82. Merck KGaA Company Details
Table 83. Merck KGaA Business Overview
Table 84. Merck KGaA Indolent Systemic Mastocytosis Treatment Product
Table 85. Merck KGaA Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 86. Merck KGaA Recent Development
Table 87. GSK Plc. Company Details
Table 88. GSK Plc. Business Overview
Table 89. GSK Plc. Indolent Systemic Mastocytosis Treatment Product
Table 90. GSK Plc. Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 91. GSK Plc. Recent Development
Table 92. Deciphera Pharmaceuticals Company Details
Table 93. Deciphera Pharmaceuticals Business Overview
Table 94. Deciphera Pharmaceuticals Indolent Systemic Mastocytosis Treatment Product
Table 95. Deciphera Pharmaceuticals Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 96. Deciphera Pharmaceuticals Recent Development
Table 97. Sanofi Aventis Company Details
Table 98. Sanofi Aventis Business Overview
Table 99. Sanofi Aventis Indolent Systemic Mastocytosis Treatment Product
Table 100. Sanofi Aventis Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 101. Sanofi Aventis Recent Development
Table 102. Eli Lilly & Company Company Details
Table 103. Eli Lilly & Company Business Overview
Table 104. Eli Lilly & Company Indolent Systemic Mastocytosis Treatment Product
Table 105. Eli Lilly & Company Revenue in Indolent Systemic Mastocytosis Treatment Business (2020-2025) & (US$ Million)
Table 106. Eli Lilly & Company Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
Table 110. Authors List of This Report
List of Figures
Figure 1. Indolent Systemic Mastocytosis Treatment Picture
Figure 2. Global Indolent Systemic Mastocytosis Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Indolent Systemic Mastocytosis Treatment Market Share by Type: 2024 VS 2031
Figure 4. Multikinase Inhibitor Features
Figure 5. Antihistamines Features
Figure 6. Other Features
Figure 7. Global Indolent Systemic Mastocytosis Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Indolent Systemic Mastocytosis Treatment Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Others Case Studies
Figure 12. Indolent Systemic Mastocytosis Treatment Report Years Considered
Figure 13. Global Indolent Systemic Mastocytosis Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Indolent Systemic Mastocytosis Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Indolent Systemic Mastocytosis Treatment Market Share by Region: 2024 VS 2031
Figure 16. Global Indolent Systemic Mastocytosis Treatment Market Share by Players in 2024
Figure 17. Global Indolent Systemic Mastocytosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Indolent Systemic Mastocytosis Treatment Revenue in 2024
Figure 19. North America Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Indolent Systemic Mastocytosis Treatment Market Share by Country (2020-2031)
Figure 21. United States Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Indolent Systemic Mastocytosis Treatment Market Share by Country (2020-2031)
Figure 25. Germany Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Indolent Systemic Mastocytosis Treatment Market Share by Region (2020-2031)
Figure 33. China Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Indolent Systemic Mastocytosis Treatment Market Share by Country (2020-2031)
Figure 41. Mexico Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Indolent Systemic Mastocytosis Treatment Market Share by Country (2020-2031)
Figure 45. Turkey Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Indolent Systemic Mastocytosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Blueprint Medicines Corporation Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 49. Allakos Inc. Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 50. AstraZeneca Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 51. Pfizer Inc. Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 52. Viatrics Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 53. Teva Pharmaceuticals Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 54. Novartis AG Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 55. Merck KGaA Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 56. GSK Plc. Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 57. Deciphera Pharmaceuticals Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 58. Sanofi Aventis Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 59. Eli Lilly & Company Revenue Growth Rate in Indolent Systemic Mastocytosis Treatment Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
